Stabilized steviol glycoside malonate

By introducing caffeoyl-substituted quinic acid as a stabilizer into steviol glycosides, the problem of poor stability of steviol glycosides under acidic conditions was solved, resulting in improved stability and extended shelf life in acidic beverages.

CN115915969BActive Publication Date: 2024-11-22CARGILL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180035857.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-04-20
Filing Date
2021-04-20
Publication Date
2024-11-22
Estimated Expiration
2041-04-20

AI Technical Summary

Technical Problem

Steviosides have poor stability under acidic conditions, which limits their application in acidic compositions such as carbonated soft drinks.

Method used

Compositions using steviol glycoside malonate (SGMA) and caffeoyl-substituted quinic acid or its salts as stabilizers are used to form compositions comprising one or more SGMAs and stabilizers, thereby optimizing their stability in acidic environments.

Benefits of technology

It improves the stability of SGMA under acidic conditions, extends its shelf life in acidic beverages, and is suitable for bottled and stored soft drinks for several months, as well as liquid water enhancers and diluted syrups for spray beverage machines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115915969B_ABST
    Figure CN115915969B_ABST
Patent Text Reader

Abstract

Various disclosed embodiments relate to stabilized steviol glycoside malonates and methods for preparing the same. The composition comprises one or more steviol glycoside malonates (SGMA) or salts thereof. The composition further comprises a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof. The composition may be a beverage or beverage concentrate having a pH of 1.7 to 4, and / or the mass ratio of the one or more SGMA, salts thereof, or combinations thereof to the stabilizer in the composition may be 1:5 to 3:1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 012,591, filed on April 20, 2020, which is incorporated herein by reference in its entirety. Background Art

[0003] In recent decades, consumers have increasingly sought low-calorie alternatives to calorie-rich products. Steviol glycosides provide a non-caloric alternative to traditional caloric sweeteners (such as sugar, glucose, sucrose and / or fructose). Steviol glycosides are a class of sweet glycosylated diterpene compounds, often derived from the leaves of Stevia rebaudiana. Various steviol glycosides are known, some of which provide a sugar-like mouthfeel characteristic and are 150 to 450 times sweeter than sugar. Such compounds are generally characterized by a single steviol backbone and the presence of differently arranged glycosidic carbohydrate residues at positions C13 and C19.

[0004] Some steviol glycosides have poor acid stability, which limits their use in acidic compositions such as carbonated soft drinks or throw syrups. Summary of the invention

[0005] In various aspects, the present invention provides a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof. The composition further comprises a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof.

[0006] In various aspects, the present invention provides a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof. The composition further comprises a stabilizer, comprising 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, salts thereof, or combinations thereof.

[0007] In various aspects, the composition can be a sweetener or sweetened composition, such as a beverage concentrate, a sweetened beverage, a carbonated soft drink, a solid food, a pharmaceutical composition, a nutritional supplement, or a dental composition.

[0008] In various aspects, the composition can be a beverage or beverage concentrate having a pH of 1.7 to 4.

[0009] In various aspects, the mass ratio of one or more SGMA, salts thereof, or combinations thereof to the stabilizer in the composition is 1:5 to 3:1.

[0010] In various aspects, 0% to 5% (by weight) of the composition can be quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, flavonols from agarwood, rhamnosin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringenin, daidze ... One or more of quercetin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peony and petunidin; or 0% to 3% (by weight) of the composition may be one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or 0% to 1% ( The composition of the present invention can be sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglyceride, diglyceride, triglyceride, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, threonose ... One or more of arabinose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomalt and inositol; or 0% to 0.5% (weight) of the composition can be one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll; or a combination thereof.

[0011] In various aspects, the present invention provides a beverage or beverage concentrate comprising one or more steviol glycoside malonates (SGMA) or salts thereof. The beverage or beverage concentrate further comprises a stabilizer. The stabilizer comprises one or more caffeoyl-substituted quinic acid or salts thereof. The pH of the beverage or beverage concentrate is 1.7 to 4. The mass ratio of one or more SGMA, salts thereof or combinations thereof to the stabilizer in the beverage or beverage concentrate is 1:5 to 3:1.

[0012] In various aspects, the present invention provides a method for preparing a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof, and further comprising a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof. The method comprises combining one or more SGMA, salts thereof, or combinations thereof with a stabilizer to form a composition.

[0013] In various aspects, the present invention provides a method for preparing a composition. The method includes combining an SGMA component with a stabilizer component to form a composition. The SGMA component comprises at least 30 wt % (wt % dwb) of one or more steviol glycoside malonate (SGMA) or a salt thereof. The stabilizer component comprises at least 30 wt % dwb of one or more caffeoyl-substituted quinic acid or a salt thereof.

[0014] In various aspects, the present invention provides a method for preparing a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof. The method comprises combining an SGMA component comprising one or more SGMA, salts thereof or combinations thereof with a stabilizer to form a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof. The SGMA component in an amount of 0% to 5% (by weight) may be quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, agaveflavonol, rhamnitzin, pyranoflavonol, furoflavonol, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringin, One or more of rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; or 0% to 3% (by weight) of the SGMA component may be one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or 0% to 1% (by weight) ) can be sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglyceride, diglyceride, triglyceride, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, suaraose, One or more of sugar, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomalt and inositol; or 0% to 0.5% (weight) of the SGMA component can be one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll; or a combination thereof.

[0015] Various embodiments of the present invention provide advantages over other compositions containing SGMA and methods of making the same. For example, in various embodiments, the compositions of the present invention can provide greater SGMA stability under acidic conditions than other compositions containing SGMA. In various embodiments, the compositions of the present invention provide greater SGMA stability under acidic conditions than corresponding compositions, which contain aspartame (currently the most commonly used artificial high-potency sweetener) instead of SGMA and one or more stabilizers of the compositions of the present invention.

[0016] SGMAs show promise as sweeteners or flavor modifiers. Unfortunately, they degrade, especially at lower pH, which limits their usefulness in certain applications such as soft drinks, beverage concentrates, and condiments. The compositions disclosed herein can increase the stability of SGMA, increasing the shelf life of products containing SGMA. This is particularly useful in soft drinks that can be bottled and stored for months, and in liquid water enhancers and dilution syrups used to make sprinkler soft drinks, both of which must be stored for months under challenging conditions before use. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The drawings illustrate generally by way of example and not by way of limitation various embodiments of the invention.

[0018] Figure 1 Shown are the percent recovery of aspartame, SGMA, and SGMA containing MCQA and DCQA acid stabilizers in a solution at pH 1.7 over time according to various embodiments. DETAILED DESCRIPTION

[0019] Reference will now be made in detail to certain embodiments of the disclosed subject matter.While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the illustrated subject matter is not intended to limit the claims to the disclosed subject matter.

[0020] Throughout the document, values ​​expressed in range format should be interpreted in a flexible manner to include not only the values ​​explicitly listed as the limits of the range, but also all individual values ​​or sub-ranges covered within the range, as if each value and sub-range were explicitly listed. For example, a range of "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted as not only including about 0.1% to about 5%, but also including individual values ​​(e.g., 1%, 2%, 3% and 4%) and sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the specified range. Unless otherwise indicated, the statement "about X to Y" has the same meaning as "about X to about Y". Similarly, unless otherwise indicated, the statement "about X, Y or about Z" has the same meaning as "about X, about Y or about Z".

[0021] In this document, unless the context clearly dictates otherwise, the terms "a", "an" or "the" are used to include one or more than one. Unless otherwise indicated, the term "or" is used to refer to a non-exclusive "or". The statement "at least one of A and B" or "at least one of A or B" has the same meaning as "A, B, or A and B". In addition, it should be understood that the words or terms used herein and not otherwise defined are for descriptive purposes only and not for purposes of limitation. Any use of section headings is intended to aid in reading the document and should not be construed as limiting; information related to a section heading may appear within or outside that particular section.

[0022] As used herein, the term "parts per million" or "ppm" refers to parts per million by weight, unless the context indicates otherwise.

[0023] In the methods described herein, the actions may be performed in any order without departing from the principles of the invention, except when a time or order of operation is explicitly enumerated. In addition, unless there is explicit declarative language stating that the specified actions are performed separately, they may be performed simultaneously. For example, a claimed action of performing X and a claimed action of performing Y may be performed simultaneously in a single operation, and the resulting process will fall within the literal scope of the claimed process.

[0024] As used herein, the term "about" can allow for a certain degree of variability in values ​​or ranges, for example, within 10%, within 5%, or within 1% of a stated limit of a stated value or range, and includes the exact stated value or stated range.

[0025] As used herein, the term "substantially" refers to a majority or majority, such as at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%. As used herein, the term "substantially free" may mean having no or insignificant amounts of a material such that the amount of material present does not affect the material properties of the composition comprising the material, such that from about 0 wt % to about 5 wt %, or from about 0 wt % to about 1 wt %, or about 5 wt % or less, or less than, equal to, about 4.5 wt %, 4 wt %, 3.5 wt %, 3 wt %, 2.5 wt %, 2 wt %, 1.5 wt %, 1 wt %, 0.9 wt %, 0.8 wt %, 0.7 wt %, 0.6 wt %, 0.5 wt %, 0.4 wt %, 0.3 wt %, 0.2 wt %, 0.1 wt %, 0.01 wt %, or about 0.001 wt % or less, or about 0 wt % of the composition is the material.

[0026] The term "hydrocarbon" as used herein refers to a molecule or functional group comprising carbon and hydrogen atoms. The term may also refer to a molecule or functional group that typically comprises carbon and hydrogen atoms, but in which all hydrogen atoms are replaced by other functional groups.

[0027] A composition comprising SGMA and a stabilizer.

[0028] Various aspects of the present invention provide a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof. The composition also comprises a stabilizer. Compared with a corresponding composition comprising less or no stabilizer, the composition can improve the stability of SGMA under acidic conditions. Compared with a corresponding composition comprising less or no stabilizer, the composition can improve the sweetness quality. The composition can be a sweetener with a relatively high concentration of SGMA, its salt, or a combination thereof. The composition can be a food product, a sweetening composition, or a beverage with a relatively low concentration of SGMA, its salt, or a combination thereof. A composition as a food product, a beverage, or a sweetening composition can be formed by combining a sweetener with other materials as a composition as a sweetener.

[0029] The composition may be a beverage such as a carbonated or non-carbonated soft drink, or a beverage concentrate such as a diluent syrup, water enhancer or flavored water enhancer, having a pH of 1.7 to 4.

[0030] The mass ratio of one or more SGMA, salts thereof or combinations thereof to the stabilizer in the composition is 1:5 to 3:1.

[0031] Many compounds may undesirably affect the flavor, aroma, color or other organoleptic aspects of the composition. To limit or eliminate such compounds, the composition may be comprised of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, flavonols from agarwood, rhamnosin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, scutellariae ... 0% to 3% (by weight) of the composition may be one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or 0% to 3% (by weight) of the composition may be one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or 0 % to 1% by weight of the composition can be sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglyceride, diglyceride, triglyceride, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose , threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomalt and inositol one or more; or 0% to 0.5% (weight) of the composition can be one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll; or a combination thereof.

[0032] The stabilizer may include one or more caffeoyl-substituted quinic acid or its salt. Caffeoyl-substituted quinic acid may include esters of carboxylic acids and alcohols of quinic acid derived from caffeic acid. The term "caffeoyl-substituted quinic acid" or "caffeoylquinic acid" used herein includes monocaffeoylquinic acid, such as chlorogenic acid (5-O-caffeoylquinic acid), neochlorogenic acid (3-O-caffeoylquinic acid) and cryptochlorogenic acid (4-O-caffeoylquinic acid), and dicaffeoylquinic acid, such as 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid) and its salt. Therefore, the stabilizer may include the acid form and salt form of the quinic acid substituted by caffeoyl.

[0033] Chlorogenic acid (5-O-caffeoylquinic acid) has the following structure:

[0034]

[0035] Neochlorogenic acid (3-O-caffeoylquinic acid) has the following structure:

[0036]

[0037] Cryptochlorogenic acid (4-O-caffeoylquinic acid) has the following structure:

[0038]

[0039] 1,5-dicaffeoylquinic acid has the following structure:

[0040]

[0041] 3,4-dicaffeoylquinic acid has the following structure:

[0042]

[0043] 1,3-Di caffeoylquinic acid has the following structure:

[0044]

[0045] 3,5-dicaffeoylquinic acid has the following structure:

[0046]

[0047] 1,4-dicaffeoylquinic acid has the following structure:

[0048]

[0049] 4,5-dicaffeoylquinic acid has the following structure:

[0050]

[0051] In various aspects, the stabilizer further comprises one or more of the following: quinic acid, caffeic acid, ferulic acid, sinapic acid, p-coumaric acid, esters of quinic acid, esters of caffeic acid, esters of ferulic acid, esters of sinapic acid, esters of p-coumaric acid, esters of caffeic acid and quinic acid, esters of caffeic acid and quinic acid comprising a single caffeic acid moiety, esters of caffeic acid and quinic acid comprising more than one caffeic acid moiety, esters of ferulic acid and quinic acid, esters of ferulic acid and quinic acid comprising a single ferulic acid moiety, esters of ferulic acid and quinic acid comprising more than one ferulic acid moiety, esters of ferulic acid and quinic acid, esters of ferulic acid and quinic acid, esters of ferulic acid and quinic acid comprising a single ferulic acid moiety, The invention relates to esters of sinapic acid and quinic acid containing a p-coumaric acid moiety, esters of sinapic acid and quinic acid containing more than one sinapic acid moiety, esters of p-coumaric acid and quinic acid, esters of p-coumaric acid and quinic acid containing a single p-coumaric acid moiety, esters of p-coumaric acid and quinic acid containing more than one p-coumaric acid moiety, diesters of quinic acid containing one caffeic acid moiety and one ferulic acid moiety, caffeic acid ester of 3-(3,4-dihydroxyphenyl)lactic acid, caffeic acid ester of tartaric acid, caffeic acid ester of tartaric acid containing more than one caffeic acid moiety, any combination thereof and / or their isomers and their corresponding salts.

[0052] Caffeic acid has the following structure:

[0053]

[0054] Quinic acid has the following structure:

[0055]

[0056] The structure provided above is for D-(–)-quinic acid and the numbers shown correspond to current IUPAC numbering.

[0057] The various compounds described herein have various stereochemical forms. For example, the compounds can be racemic mixtures of any degree of enrichment, enantiomerically pure compounds, and enantiomerically enriched mixtures. Individual optical isomers can be separated or synthesized so that they are substantially free of their enantiomers or diastereomeric partners, and these are within the scope of the present invention. In various embodiments, the compounds are used in their naturally occurring stereochemical forms. For example, the compounds can be in their botanically occurring stereochemical forms.

[0058] In some aspects, the stabilizer comprises one or more of the following substances: chlorogenic acid (5-O-caffeoylquinic acid), neochlorogenic acid (3-O-caffeoylquinic acid), cryptochlorogenic acid (4-O-caffeoylquinic acid), 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-O-feruloylquinic acid, 4-O-feruloylquinic acid, 5-O-feruloylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, rosmarinic acid, caffeoyltartaric acid (monocaffeoyltartaric acid), chicoric acid (dicaffeoyltartaric acid) and salts, any combination thereof and / or their isomers and corresponding salts.

[0059]

[0060] In various fields, stabilizer comprises one or more compounds and salts thereof according to formula I. According to formula I, R is H or optionally substituted cinnamoyl, and X is H (acid form) or M (salt form), wherein M is a cationic metal such as sodium, potassium or a mixture thereof, to produce a salt. The example of optionally substituted cinnamoyl includes but is not limited to caffeoyl, o-coumaroyl, p-coumaroyl, m-coumaroyl, cinnamoyl, 4-hydroxycinnamoyl, feruloyl, isoferuloyl or sinapinic acid. In various embodiments, at least one R is optionally substituted cinnamoyl, at least two R are optionally substituted cinnamoyl, or just one R or two R are optionally substituted cinnamoyl. In various embodiments, at least one R is caffeoyl, at least two R are caffeoyl, or just one R or two R are caffeoyl.

[0061] The stabilizer may be composed of one or more compounds selected from the group consisting of chlorogenic acid (5-O-caffeoylquinic acid), neochlorogenic acid (3-O-caffeoylquinic acid), cryptochlorogenic acid (4-O-caffeoylquinic acid), 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid and any combination thereof, their isomers and corresponding salts. In various embodiments, one or more alcohols of the caffeoyl moiety are replaced by hydrogen or by C1-C 10 Alkyl (such as methyl, ethyl, propyl, etc.), C1-C 10 Alkenyl, C6-C 10 Aryl, C2-C 10The modified and substituted caffeic acid moieties can be substituted with cinnamic acid, o-coumaryl, p-coumaryl, m-coumaryl, cinnamoyl, 4-hydroxycinnamoyl, ferulic acid, isoferulic acid, sinapinic acid, gallic acid, sulfate, phosphate or phosphonate. Thus, the modified and substituted caffeic acid moieties can be substituted with cinnamic acid, o-coumaryl, p-coumaric acid, m-coumaric acid, ferulic acid and their acyl and ester forms. In various embodiments, the one or more alcohols of the quinic acid moiety are replaced with C1-C 10 Alkyl (such as methyl, ethyl, propyl, etc.), C1-C 10 Alkenyl, C6-C 10 Aryl, C2-C 10 The invention can be substituted with acyl, acrylate, caffeoyl, o-coumaroyl, p-coumaroyl, m-coumaroyl, cinnamoyl, 4-hydroxycinnamoyl, feruloyl, isoferuloyl, sinapoyl, galloyl, sulfate, phosphate or phosphonate.

[0062] The stabilizer may include one or more of the following: caffeic acid ester of 3-(3,4-dihydroxyphenyl)lactic acid, caffeic acid ester of tartaric acid, ferulic acid ester of quinic acid, or any other optionally substituted cinnamoyl ester of quinic acid other than caffeoylquinic acid. Examples of ferulic acid esters of quinic acid include 3-O-ferulylquinic acid, 4-O-ferulylquinic acid, 5-O-ferulylquinic acid, 3,4-diferulylquinic acid, 3,5-diferulylquinic acid, 4,5-diferulylquinic acid, and combinations thereof. Examples of caffeic acid esters of 3-(3,4-dihydroxyphenyl)lactic acid are rosmarinic acid. Examples of caffeic acid esters of tartaric acid include chicoric acid, caffeoyltartaric acid, monocaffeoyltartaric acid, dicaffeoyltartaric acid, and combinations thereof.

[0063] In an alternative embodiment, the stabilizer is a mixture consisting of one or more of caffeic acid ester of 3-(3,4-dihydroxyphenyl)lactic acid, caffeic acid ester of tartaric acid, ferulic acid ester of quinic acid, or any other optionally substituted cinnamoyl quinic acid ester other than caffeoylquinic acid. Such stabilizers also include salts thereof so as to have a salt fraction and an acid fraction. Therefore, it is also contemplated that each of the various embodiments described herein involving caffeoylquinic acid and other stabilizers may be equally applicable to this alternative.

[0064] The stabilizer may include 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, salts thereof, or combinations thereof.

[0065] The stabilizer may include one or more monocaffeoylquinic acid, dicaffeoylquinic acid, their salts or combinations thereof. The stabilizer may include a mixture of one or more monocaffeoylquinic acid, their salts or combinations thereof; and one or more dicaffeoylquinic acid, their salts or combinations thereof. The monocaffeoylquinic acid may be one or more of 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid or 5-O-caffeoylquinic acid. The monocaffeoylquinic acid salt may be one or more of 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid or 5-O-caffeoylquinic acid salt. The dicaffeoylquinic acid may be one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid or 4,5-dicaffeoylquinic acid. The dicaffeoylquinate may be one or more of 1,3-dicaffeoylquinate, 1,4-dicaffeoylquinate, 1,5-dicaffeoylquinate, 3,4-dicaffeoylquinate, 3,5-dicaffeoylquinate, or 4,5-dicaffeoylquinate. The salt of monocaffeoylquinic acid or the salt of dicaffeoylquinic acid may contain a counter ion that is sodium, potassium, calcium, magnesium, ammonium, or a combination thereof. The salt of monocaffeoylquinic acid or the salt of dicaffeoylquinic acid may contain a counter ion that is sodium, potassium, or a combination thereof.

[0066] The one or more SGMA, its salt or combination thereof can be in any suitable proportion of the composition. The one or more SGMA, its salt or combination thereof can be 0.001% to 99.999%, 5% to 99.999%, 10% to 99.999%, 0.01% to 90%, 0.01% to 30%, or 0.001% or more by weight of the composition, or less than, equal to, or greater than 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 8%, 10%, 12%, 14%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 9 %, 18 wt %, 20 wt %, 22 wt %, 24 wt %, 26 wt %, 28 wt %, 30 wt %, 32 wt %, 34 wt %, 36 wt %, 38 wt %, 40 wt %, 45 wt %, 50 wt %, 55 wt %, 60 wt %, 65 wt %, 70 wt %, 75 wt %, 80 wt %, 82 wt %, 84 wt %, 86 wt %, 88 wt %, 90 wt %, 92 wt %, 94 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, 99 wt %, 99.9 wt %, or 99.999 wt % or less. Compositions as sweeteners can have relatively high concentrations of one or more SGMA, salts thereof, or combinations thereof, such as 0.2 wt % to 99.999 wt %, or 5 wt % to 99.999 wt %. Compositions that are beverages such as carbonated soft drinks can have relatively low concentrations of one or more SGMAs, salts thereof, or combinations thereof, such as 0.01 wt % to 0.2 wt %, or 0.02 wt % to 0.1 wt %, or 0.03 wt % to 0.07 wt %.

[0067] The composition can have any suitable concentration of one or more SGMA, salts thereof, or combinations thereof, such as from 100 ppm to 500,000 ppm (i.e., parts per million by weight), from 100 ppm to 2,000 ppm, from 200 ppm to 1,000 ppm, from 300 ppm to 700 ppm, or 100 ppm or more, or less than, equal to, or greater than 150 ppm, 200 ppm, 250 ppm, 300 ppm, 350 ppm, 400 ppm, 450 ppm, 500 ppm, 550 ppm, 600 ppm, 650 ppm, 700 ppm, 750 ppm, 800 ppm, 850 ppm, 900 ppm, 950 ppm, 1,000 ppm, 1,100 ppm, or more. 0ppm, 1,200ppm, 1,300ppm, 1,400ppm, 1,500ppm, 1,600ppm, 1,700ppm, 1,800ppm, 1,900ppm, 2,000ppm, 2,200ppm, 2,400ppm, 2,600ppm, 2,800ppm, 3,000ppm, 3,500ppm, 4,000ppm, 5,000ppm, 6,000ppm, 8,000ppm, 10,000ppm, 20,000ppm, 50,000ppm, 100,000ppm, 200,000ppm, 300,000ppm or 400,000ppm or 500,000ppm or less. Compositions used as sweeteners may have relatively high concentrations of one or more SGMA, salts thereof, or combinations thereof, such as 100,000 ppm to 500,000 ppm or more. Compositions used as beverages, such as carbonated soft drinks, may have relatively low concentrations of one or more SGMA, salts thereof, or combinations thereof, such as 100 ppm to 2,000 ppm, 200 ppm to 1,000 ppm, or 300 ppm to 700 ppm.

[0068] The stabilizer can be any suitable proportion of the composition. The stabilizer can be 0.001% to 99.999%, 5% to 99.999%, 10% to 99.999%, 0.01% to 90%, 0.01% to 30%, or 0.001% or more by weight of the composition, or less than, equal to, or greater than 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 8%, 10%, 12%, 14%, 16%, 18% by weight of the composition. %, 20 % by weight, 22 % by weight, 24 % by weight, 26 % by weight, 28 % by weight, 30 % by weight, 32 % by weight, 34 % by weight, 36 % by weight, 38 % by weight, 40 % by weight, 45 % by weight, 50 % by weight, 55 % by weight, 60 % by weight, 65 % by weight, 70 % by weight, 75 % by weight, 80 % by weight, 82 % by weight, 84 % by weight, 86 % by weight, 88 % by weight, 90 % by weight, 92 % by weight, 94 % by weight, 95 % by weight, 96 % by weight, 97 % by weight, 98 % by weight, 99 % by weight, 99.9 % by weight or 99.999 % by weight or less. The composition as a sweetener can have a relatively high concentration of stabilizer, such as 0.2 % by weight to 99.999 % by weight, or 5 % by weight to 99.999 % by weight. Compositions that are beverages such as carbonated soft drinks may have relatively low concentrations of stabilizer, such as 0.01 wt % to 0.2 wt %, or 0.02 wt % to 0.1 wt %, or 0.03 wt % to 0.07 wt %.

[0069] The composition can have any suitable concentration of the stabilizer. For example, the concentration of the stabilizer can be 100 ppm to 500,000 ppm (i.e., parts per million by weight), 100 ppm to 2,000 ppm, 200 ppm to 1,000 ppm, 300 ppm to 700 ppm, or 100 ppm or more, or less than, equal to, or greater than 150 ppm, 200 ppm, 250 ppm, 300 ppm, 350 ppm, 400 ppm, 450 ppm, 500 ppm, 550 ppm, 600 ppm, 650 ppm, 700 ppm, 750 ppm, 800 ppm, 850 ppm, 900 ppm, 950 ppm, 1,000 ppm, 1,100 ppm, 1,200 ppm, 1 pm, 1,300ppm, 1,400ppm, 1,500ppm, 1,600ppm, 1,700ppm, 1,800ppm, 1,900ppm, 2,000ppm, 2,200ppm, 2,400ppm, 2,600ppm, 2,800ppm, 3,000ppm, 3,500p pm, 4,000ppm, 5,000ppm, 6,000ppm, 8,000ppm, 10,000ppm, 20,000ppm, 50,000ppm, 100,000ppm, 200,000ppm, 300,000ppm or 400,000ppm or 500,000ppm or less. Compositions as sweeteners may have relatively high concentrations of stabilizers, such as 2,000 ppm to 500,000 ppm or more, for example 3,000 to 300,000 ppm, 4,000 ppm to 250,000 ppm or 5,000 ppm to 200,000 ppm. Compositions as beverages such as carbonated soft drinks may have relatively low concentrations of stabilizers, such as 100 ppm to 2,000 ppm, 200 ppm to 1,000 ppm or 300 ppm to 700 ppm.

[0070] The composition can have any suitable mass ratio of one or more SGMA, salts thereof, or combinations thereof to the stabilizer, such as 0.1:1 to 10:1, 1:5 to 3:1, 0.3:1 to 3:1, 0.5:1 to 2:1, or 0.1:1 or greater, or less than, equal to, or greater than 0.2:1 (e.g., 1:5), 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1.0:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1, 1.7:1, 1.8:1, 1.9:1, 2.0:1, 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3.0:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.8:1, 4.0:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, 7.5:1, 8:1, 8.5:1, 9:1, 9.5:1 or 10:1 or less.

[0071] The composition may be substantially free (e.g., 0% by weight) of non-malonated steviol glycosides and salts thereof. The composition may include one or more non-malonated steviol glycosides, salts thereof, or combinations thereof. The non-malonated steviol glycoside or salt thereof may be any suitable non-malonated steviol glycoside or salt thereof, such as stevioside, rebaudioside A, rebaudioside C, dulcoside A, rebaudioside B, rebaudioside D, rebaudioside E, rebaudioside M, rebaudioside O, rebaudioside N, rebaudioside F, salts thereof, or combinations thereof. The composition can have any suitable ratio (i.e., mass ratio) of non-malonated steviol glycosides, salts thereof, or combinations thereof to one or more SGMAs, such as 0.001:1 to 1000:1, 0.1:1 to 1000:1, 2:1 to 1000:1, or 0.001:1 or greater, or less than, equal to, or greater than 0.005:1, 0.01:1, 0.05:1, 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1. 1, 0.8:1, 0.9:1, 1.0:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 8:1, 10:1, 15:1, 20:1, 25:1, 50:1, 100:1, 150:1, 200:1, 250:1, 500:1, or 750:1 or 1000:1 or less. In some useful embodiments, the composition has a relatively low content of non-malonated steviol glycosides, for example, a ratio of non-malonated steviol glycosides, salts thereof, or combinations thereof to one or more SGMAs of less than 0.3:1, for example, 0 (i.e., no non-malonated steviol glycosides are present) to 0.3:1, 0 to 0.2:1, 0 to 0.1:1, 0 to 0.05:1, 0 to 0.01:1, 0 to 0.005:1, or 0 to 0.001:1.

[0072] Said composition can be an aqueous composition.For example, 20 % by weight or more, or at least 20 % by weight of water, or said composition can be water.Any suitable amount of composition can be water, such as 5 % by weight or more, or be less than, equal to or greater than 6 % by weight, 8 % by weight, 10 % by weight, 15 % by weight, 20 % by weight, 25 % by weight, 30 % by weight, 35 % by weight, 40 % by weight, 45 % by weight, 50 % by weight, 55 % by weight, 60 % by weight, 65 % by weight, 70 % by weight, 75 % by weight, 80 % by weight, 82 % by weight, 84 % by weight, 86 % by weight, 88 % by weight, 90 % by weight, 92 % by weight, 94 % by weight, 96 % by weight, 97 % by weight or 98 % by weight or more.

[0073] The composition can have any suitable pH, such as a pH of 1 to 9, e.g., 1 to 7, 1.5 to 6, 1.7 to 4, 2.5 to 3.5 (e.g., beverages such as carbonated soft drinks), 1.7 to 2.0 (e.g., beverage concentrates such as diluted syrups), or both less than 9 and less than, equal to, or greater than 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, 5, 5.5, 6, 6.5, 7, 7.5, 8, or 8.5.

[0074] The composition can have a solid form (e.g., not a liquid composition), such as a powder or granular solid. The composition can be a freeze-dried powder. The composition can be a sweetener. The composition in solid form can have any suitable solubility in water. For example, the solid composition can have a solubility in water of 80 wt % or more (i.e., at 22°C, the solid composition is dissolved in deionized water to form an aqueous solution, wherein the solid composition is 80 wt % or more), or 1 wt % to 80 wt %, or 40 wt % to 80 wt %, or 0 wt %, or less than, equal to or greater than 2 wt %, 4 wt %, 6 wt %, 8 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, 35 wt %, 40 wt %, 45 wt %, 50 wt %, 55 wt %, 60 wt %, 65 wt %, 70 wt % or 75 wt % or 80 wt % or less.

[0075] The composition can be a solid food material, such as a snack, a dry fruit product, a biscuit, a cereal, a chocolate, a chewing gum, a candy, a cake, a donut, or a combination thereof. The composition can be a pharmaceutical composition, a nutritional supplement, a dental composition, or a combination thereof.

[0076] The composition may be a sweetened beverage. The composition may be chocolate milk, tea, energy drink, drinkable yogurt, flavored water, or a combination thereof. The composition may be a soft drink, i.e., a flavored beverage without alcohol, such as a carbonated soft drink. The composition may be a beverage concentrate, such as a liquid water enhancer for flavoring or sweetening still water or a diluent syrup that may be used to prepare a carbonated soft drink by adding water and carbonation. The composition may be a sweetener, and may be a liquid, a solid, or a combination thereof.

[0077] The composition may include any suitable one or more additional components, or may be substantially free of one or more additional components. Examples of the one or more additional components include another stabilizer (e.g., another material or materials other than a stabilizer comprising one or more caffeoyl-substituted quinic acids or salts thereof, which stabilize the composition to acidic conditions), a microbial stabilizer (e.g., sodium benzoate or sodium sorbate), another sweetener, a bulking agent, erythritol, a desiccant, an anti-caking agent, or a combination thereof.

[0078] The composition can be substantially free of Stevia plant material that is insoluble in water or a water-miscible alcohol such as ethanol or methanol.

[0079] In various aspects, the composition can be stable under acidic conditions in the absence of a steviol glycoside stabilizer that stabilizes steviol glycosides to acidic conditions (e.g., prevents or significantly limits degradation). Degradation can include, for example, hydrolysis of the malonyl ester bonds of SGMA. Measuring changes in total SGMA content can be a suitable measure of the amount of degradation that has occurred. SGMA, its salts, or combinations thereof can degrade more slowly over time under acidic conditions (e.g., at pH 1.7 to 4) compared to corresponding compositions containing less or no stabilizer. For example, the SGMA in the composition has a pH of 1 to 9, 1.7 to 4, 2.5 to 3.5, 1.7 to 2.0, 4 to 9, or 1 or more, or less than, equal to, or greater than 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, or 9 or less can be stable (e.g., the SGMA or a salt thereof degrades by less than 20 wt%, 10 wt%, 5 wt%, 1 wt%, or less than 0.1 wt% at 22°C for 4 weeks, 2 months, 4 months, 6 months, 1 year, 2 years, or 3 years or more).

[0080] In one suitable standardized test for measuring the degradation of SGMA in a composition, the composition is dissolved in an alcohol-free buffered citric acid aqueous solution having a SGMA concentration of 50,000 ppm (5% by weight) and a pH of 1.7 and stored at 22°C. This degradation test can be used to measure degradation over a fixed period of time. For example, the composition of the present invention may have an SGMA content equal to or greater than 85%, 90%, 92%, 94%, 95%, 96%, or 97% or 98% by weight or more of the SGMA content present at the beginning of the test after 7 days. This degradation test can also be used to measure the time required to reach a fixed amount of degradation. For example, the composition of the present invention may have an SGMA content of at least 90% by weight of the SGMA content present at the beginning of the test after storage for at least 4 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, or at least 20 days. A composition having a pH of 1.7 at 22°C for 5 days may be stable such that 90% by weight or more of SGMA, its salt, or a combination thereof is not degraded. The composition having a pH of 1.7 can be stable over 35 days at 22°C such that 50 wt% or more of the SGMA, a salt thereof, or a combination thereof has not been degraded.

[0081] The composition can be substantially free of materials from the stevia leaf that are removed during the chromatographic separation process to obtain the SGMA or salt thereof of the composition. For example, the composition can be substantially free of organic acids, citric acid, malic acid, phosphates, sulfates, chromoplasts, chlorophyll, flavonoids, rutin, quercetin, quercetin, glucose, fructose, amino acids, proteins, MCQA, DCQA, or combinations thereof.

[0082] Some compounds may adversely affect the flavor or fragrance of the composition. In various aspects, the composition does not contain one or more or any combination of the compounds shown in Table 1 that exceed the disclosed preferred content levels. All preferred content levels are expressed as weight percent based on dry weight. For those compounds listed as acids, the compound can exist in acid form and / or salt form.

[0083] Table 1 .

[0084]

[0085]

[0086]

[0087] In one aspect, the composition in solid (dry) form does not contain one or more or any combination of the following compounds in Table 2 above the disclosed preferred content levels. All preferred content levels are expressed as weight percent based on dry weight. For those compounds listed as acids, the compound can exist in acid form and / or salt form.

[0088] Table 2 .

[0089]

[0090]

[0091] In one aspect, the composition does not contain one or more of the following compounds in Table 3 above the disclosed preferred content levels or any combination thereof. These preferred content levels are expressed as a weight percentage of a liquid composition (e.g., a liquid sweetener concentrate, such as a dilute syrup). For those compounds listed as acids, the compound may exist in acid form and / or salt form, taking into account that any one may dissociate in the composition.

[0092] Table 3 .

[0093]

[0094]

[0095] In one aspect, the composition is a liquid sweetener concentrate or beverage and is not included in one or more or any combination of the following compounds listed in Table 4 of the disclosed weight % critical values. All preferred content levels are represented by the weight percent of the total liquid sweetener concentrate or beverage. For those compounds listed as acid, considering that any one may dissociate in the beverage, the compound can exist in acid form and / or salt form.

[0096] Table 4 .

[0097]

[0098]

[0099] Steviol glycoside malonate .

[0100] The composition of the present invention comprises steviol glycoside malonate (SGMA) or a salt thereof. SGMA comprises one or more malonate groups, such as 1 to 3 or more malonate groups (e.g., no more than 1 to 3 malonate groups), 2 malonate groups (e.g., no more than 2 malonate groups), or 1 malonate group (e.g., no more than 1 malonate group). The malonate group may have the following structure:

[0101]

[0102] or a salt thereof.

[0103] The SGMA salt can be any suitable salt of SGMA. For example, the salt can be a malonate salt comprising a counterion that is sodium, potassium, calcium, magnesium, ammonium, or a combination thereof. The salt can be a malonate salt comprising a counterion that is sodium, potassium, or a combination thereof.

[0104] SGMA can be any suitable steviol glycoside containing a malonate group. SGMA can contain one or more of glucose, xylose, rhamnose or a combination thereof. SGMA can have the following structure:

[0105]

[0106] or a salt thereof. At each occurrence, R 1 Can be independently selected from-H, malonate or its salt and the primary sugar of glycosidic bonding.When each occurrence, primary sugar can be independently selected from glucose, xylose and rhamnose, and when each occurrence, primary sugar can independently optionally include the secondary sugar of primary sugar glycosidic bonding, malonate or its salt or their combination with primary sugar bonding.When each occurrence, secondary sugar (if present) can be independently selected from glucose, xylose and rhamnose, and when each occurrence, secondary sugar can independently optionally include the tertiary sugar of secondary sugar glycosidic bonding, malonate or its salt or their combination with secondary sugar bonding.When each occurrence, tertiary sugar (if present) can be independently selected from glucose, xylose and rhamnose, and when each occurrence, tertiary sugar can independently optionally include the malonate or its salt bonded with tertiary sugar.SGMA includes at least one of primary sugar and at least one of malonate group or its salt.

[0107] SGMA may be free of secondary sugars. SGMA may include at least one of the secondary sugars. SGMA may be free of tertiary sugars. SGMA may include at least one of the tertiary sugars.

[0108] SGMA can have the following structures:

[0109]

[0110] or a salt thereof. At each occurrence, R a R-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0111] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0112]

[0113] Or a salt thereof. SGMA may have the following structure:

[0114]

[0115] or a salt thereof.

[0116] SGMA can have the following structures:

[0117]

[0118] or a salt thereof. At each occurrence, R a R-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0119] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0120]

[0121] Or a salt thereof. SGMA may have the following structure:

[0122]

[0123] Or a salt thereof. SGMA may have the following structure:

[0124]

[0125] or a salt thereof.

[0126] SGMA can have the following structures:

[0127]

[0128] or a salt thereof. At each occurrence, R a R-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0129] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0130]

[0131] Or a salt thereof. SGMA may have the following structure:

[0132]

[0133] or a salt thereof.

[0134] SGMA can have the following structures:

[0135]

[0136] or a salt thereof. At each occurrence, R aR-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0137] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0138]

[0139] or a salt thereof.

[0140] SGMA can have the following structures:

[0141]

[0142] or a salt thereof. At each occurrence, R a R-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof bonded thereto, or a combination thereof).

[0143] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0144]

[0145] or a salt thereof.

[0146] SGMA can have the following structures:

[0147]

[0148] or a salt thereof. At each occurrence, R aR-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0149] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0150]

[0151] or a salt thereof.

[0152] SGMA can have the following structures:

[0153]

[0154] or a salt thereof. At each occurrence, R a R-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0155] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0156]

[0157] or a salt thereof.

[0158] SGMA can have the following structures:

[0159]

[0160] or a salt thereof. At each occurrence, R aR-H, malonate or its salt, and sugar. At each occurrence, the sugar may be independently selected from glucose, xylose, and rhamnose. At each occurrence, the sugar may independently optionally include a malonate or its salt bonded to the sugar. For example, each of the sugars may independently be free of a malonate or its salt bonded thereto, or may include a malonate or its salt bonded thereto. SGMA includes at least one malonate or its salt (e.g., one or more R-H, malonate or its salt) a is a malonate or a salt thereof, one or more sugars contain a malonate or a salt thereof or a combination thereof bonded thereto).

[0161] At each occurrence, R a may be independently selected from -H and malonate or its salt, wherein at least one R a It is a malonate or a salt thereof. SGMA may have the following structure:

[0162]

[0163] Or a salt thereof. SGMA may have the following structure:

[0164]

[0165] or a salt thereof.

[0166] SGMA can have any suitable solubility in water. For example, SGMA can have a solubility in water of 40 wt % or more (i.e., SGMA is dissolved in deionized water at 22°C to form an aqueous solution of 40 wt % or more SGMA), or 0 wt % to 40 wt %, or 20 wt % to 40 wt %, or 0 wt %, or 1 wt % or less, or less than, equal to, or greater than 2 wt %, 4 wt %, 6 wt %, 8 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, 35 wt %, or 40 wt % or more.

[0167] Method for preparing a composition comprising SGMA and a stabilizer

[0168] Various aspects of the present invention provide a method for preparing a composition comprising one or more SGMA or a salt thereof and a stabilizer. The method can be any suitable method for forming a composition. The method can include combining one or more SGMA, a salt thereof, or a combination thereof with a stabilizer to form a composition.

[0169] Various aspects of the present invention provide a method for preparing a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof. The method may include combining an SGMA component comprising one or more SGMA, salts thereof, or combinations thereof with a stabilizer component comprising a stabilizer to form a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof.

[0170] SGMA, its salt or a combination thereof can be any suitable ratio of the SGMA component. However, preferably, at least 30 wt% of the SGMA component on a dry weight basis (wt% dwb) is SGMA, its salt or a combination thereof. For example, the SGMA, its salt, or a combination thereof can be 30 wt % dwb to 99.9 wt % dwb, 40 wt % dwb to 99.9 wt % dwb, 50 wt % dwb to 99.9 wt % dwb, 80 wt % dwb to 99.9 wt % dwb, 90 wt % dwb to 99.9 wt % dwb, or at least 5 wt % dwb of both and less than, equal to, or greater than 6 wt % dwb, 7 wt % dwb, 8 wt % dwb, 10 wt % dwb, 12 wt % dwb, 14 wt % dwb, 16 wt % dwb, 18 wt % dwb, 20 wt % dwb, 22 wt % dwb, 24 wt % dwb, 26 wt % dwb, 28 wt % dwb, % dwb, 30 wt % dwb, 32 wt % dwb, 34 wt % dwb, 36 wt % dwb, 38 wt % dwb, 40 wt % dwb, 45 wt % dwb, 50 wt % dwb, 55 wt % dwb, 60 wt % dwb, 65 wt % dwb, 70 wt % dwb, 75 wt % dwb, 80 wt % dwb, 82 wt % dwb, 84 wt % dwb, 86 wt % dwb, 88 wt % dwb, 90 wt % dwb, 92 wt % dwb, 94 wt % dwb, 95 wt % dwb, 96 wt % dwb, 97 wt % dwb, 98 wt % dwb, 99 wt % dwb, 99.9 wt % dwb or 99.99 wt % dwb. When used, the SGMA component may be in dry solid form or in solution, such as a non-alcoholic aqueous solution.

[0171] The stabilizer component may comprise any suitable proportion, preferably at least 30 wt % dwb (e.g., 30 wt % dwb to 99.9 wt % dwb, 40 wt % dwb to 99.9 wt % dwb, 50 wt % dwb to 99.9 wt % dwb, 80 wt % dwb to 99.9 wt % dwb, 90 wt % dwb to 99.9 wt % dwb) of the following acids and esters: quinic acid, caffeic acid, ferulic acid, sinapinic acid, p-coumaric acid, esters of quinic acid, esters of caffeic acid, esters of ferulic acid, esters of sinapinic acid, esters of p-coumaric acid, esters of caffeic acid and quinic acid, esters of caffeic acid and quinic acid containing a single caffeic acid moiety, esters of caffeic acid and quinic acid containing more than one caffeic acid moiety, esters of ferulic acid and quinic acid. , esters of ferulic acid and quinic acid containing a single ferulic acid moiety, esters of ferulic acid and quinic acid containing more than one ferulic acid moiety, esters of sinapinic acid and quinic acid, esters of sinapinic acid and quinic acid containing a single sinapinic acid moiety, esters of sinapinic acid and quinic acid containing more than one sinapinic acid moiety, esters of p-coumaric acid and quinic acid, esters of p-coumaric acid and quinic acid containing a single p-coumaric acid moiety, esters of p-coumaric acid and quinic acid containing more than one p-coumaric acid moiety, diesters of quinic acid containing one caffeic acid moiety and one ferulic acid moiety, caffeic acid ester of 3-(3,4-dihydroxyphenyl)lactic acid, caffeic acid ester of tartaric acid, caffeic acid ester of tartaric acid containing more than one caffeic acid moiety, any combination thereof and / or their isomers and their corresponding salts. The stabilizer may contain one or more caffeoyl-substituted quinic acids or salts thereof. However, preferably, at least 30 wt% dwb of the stabilizer component is one or more caffeoyl-substituted quinic acids or salts thereof, such as one or more monocaffeoylquinic acids, dicaffeoylquinic acids, salts thereof, or combinations thereof.For example, the one or more caffeoyl-substituted quinic acid or salt thereof can be 30 wt % dwb to 99.9 wt % dwb, 40 wt % dwb to 99.9 wt % dwb, 50 wt % dwb to 99.9 wt % dwb, 80 wt % dwb to 99.9 wt % dwb, 90 wt % dwb to 99.9 wt % dwb, or at least 5 wt % dwb and less than, equal to, or greater than 6 wt % dwb, 7 wt % dwb, 8 wt % dwb, 10 wt % dwb, 12 wt % dwb, 14 wt % dwb, 16 wt % dwb, 18 wt % dwb, 20 wt % dwb, 22 wt % dwb, 24 wt % dwb, 26 wt % dwb, 28 wt % dwb, dwb, 30 wt % dwb, 32 wt % dwb, 34 wt % dwb, 36 wt % dwb, 38 wt % dwb, 40 wt % dwb, 45 wt % dwb, 50 wt % dwb, 55 wt % dwb, 60 wt % dwb, 65 wt % dwb, 70 wt % dwb, 75 wt % dwb, 80 wt % dwb, 82 wt % dwb, 84 wt % dwb, 86 wt % dwb, 88 wt % dwb, 90 wt % dwb, 92 wt % dwb, 94 wt % dwb, 95 wt % dwb, 96 wt % dwb, 97 wt % dwb, 98 wt % dwb, 99 wt % dwb, 99.9 wt % dwb or 99.99 wt % dwb. When used, the stabilizer component may be in dry solid form or in solution, such as a non-alcoholic aqueous solution.

[0172] Various aspects of the present invention provide methods for preparing compositions such as sweeteners or sweetened compositions. The sweetened composition can be a beverage concentrate (e.g., a dilute syrup, a water enhancer, or a flavored water enhancer), a sweetened beverage (e.g., tea or carbonated soft drinks), a solid food material, a pharmaceutical composition, a nutritional supplement, or a dental composition. The method may include combining an SGMA component comprising one or more SGMAs with a stabilizer component comprising one or more stabilizers to form a composition. In order to form beverages and beverage concentrates, the SGMA component and the stabilizer component may be combined before being added to the beverage or concentrate, may be added to the beverage or concentrate alone, or may be added alone to another composition that is also added to the beverage or concentrate. In various aspects, the composition is a beverage or beverage concentrate, and the method also includes combining an SGMA component and a stabilizer component in an aqueous solution having a pH of 1 to 6. The SGMA component and the stabilizer component may be combined before being added to the aqueous solution, and the SGMA component and the stabilizer component may be added to the aqueous solution alone, or may be added alone to another composition that is also added to the beverage.

[0173] Either and preferably both of the SGMA component and the stabilizer component may contain 0% to 5% (by weight) of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, agaveflavonol, rhamnitzin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein , daidzein, glycitein, hesperidin, naringin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; or 0% to 3% (by weight) of one of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid or more; or 0% to 1% (by weight) of sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglyceride, diglyceride, triglyceride, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, One or more of erythrose, threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomalt and inositol; or 0% to 0.5% (by weight) of one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll; or a combination thereof.

[0174] Either and preferably both of the SGMA component and the stabilizer component may be free of or have limited content of compounds that may adversely affect flavor or aroma. For example, either or both of the SGMA component and the stabilizer component, the precursor does not contain one or more of the compounds shown in Tables 1 to 4 or any combination thereof above the disclosed preferred content levels. The SGMA component may be similar or identical to an embodiment of a composition comprising one or more SGMA or salts thereof described herein but lacking the stabilizer component added in the method.

[0175] Example

[0176] Various embodiments of the present invention may be better understood by reference to the following examples which are provided by way of illustration.The present invention is not limited to the examples given herein.

[0177] Example 1 Stability of Malonated Steviol Glycosides .

[0178] SGMA was obtained from Stevia leaves as follows. Powdered dried Stevia leaves (160 g) were extracted with 50% vol / vol aqueous ethanol (1600 mL) for 60 minutes with occasional stirring. Solid plant matter was removed by filtering with a Buchner funnel and Whatman 54 filter paper. The remaining plant matter was washed with an additional volume of 50% vol / vol aqueous ethanol (800 mL). The initial extract was treated with ethyl acetate (1:1 extraction volume) to remove hydrophobic color bodies, and any residual ethyl acetate was evaporated under a stream of nitrogen. The clarified extract was then passed through an anionic resin (Dowex 66) to bind ionic SGMA species. The resin was washed with aqueous ethanol (50%) to remove all neutral species, including traditional SG. The SGMA was then eluted with an ethanol aqueous solution (50%) containing 5% sodium acetate. The eluate was collected and dried to remove excess ethanol. Once <10% ethanol remained, the eluate was acidified to pH 1 to 2 with HCl and desalted by direct loading on a hydrophobic resin (Diaion Sepabeads SP70), followed by washing with 15% vol / vol ethanol and eluting with 70% ethanol. The desalted eluate was then dried under nitrogen to remove the ethanol and lyophilized to complete dryness.

[0179] The degradation of steviol glycoside malonate (SGMA) was benchmarked against aspartame. Aspartame has demonstrated commercially acceptable shelf life in a variety of common retail food and beverage products, including many carbonated soft drinks at pH below 4. Initial testing demonstrated that SGMA was less stable than aspartame at pH 1.7 and 3.0 without a stabilizer.

[0180] Stabilizers were formed by extracting and purifying monocaffeoylquinic acid (MCQA) and dicaffeoylquinic acid (DCQA) from mate leaves. Mate leaves (300 g) were added to a glass container, 50% vol / vol ethanol aqueous solution (1500 mL) was also added, and extracted for 60 minutes with occasional stirring. The solution was filtered through a Buchner funnel and Whatman 54 filter paper. The remaining plant matter was washed with additional water to increase the yield and obtain an extract containing 35% ethanol (vol / vol). The extract was loaded onto an ion exchange resin (Amberlite FPA53) and the resin was washed with 35% ethanol (vol / vol). MCQA and DCQA were eluted with a 50% ethanol (vol / vol) solution containing 10% (wt / vol) sodium chloride. Ethanol was evaporated from the eluent and the pH was adjusted to 1 to 2 with HCl. The acidified solution was loaded onto a hydrophobic resin (Diaion Sepabeads SP70), the resin was washed with 10% ethanol in water (vol / vol), acidified to pH <2 with HCl, and then washed with pure water to desalt MCQA and DCQA. The compounds were eluted with 70% ethanol in water, and ethanol was evaporated from the eluent solution. The solution was decolorized by membrane ultrafiltration (3 kDa nominal molecular weight cutoff, TurboClean NP010). The decolorized permeate was concentrated and then lyophilized to dryness to obtain a stabilizer.

[0181] Acid stability measurements were performed on samples of aspartame, SGMA, and a combination of SGMA and stabilizers. The sample containing SGMA and stabilizers had a weight ratio of 1:1 of SGMA to MCQA and DCQA. Acid stability was measured in water at a pH of 1.7. The concentration of aspartame or SGMA in the sample during the test was 0.1% to 10% by weight. The samples were stored at room temperature (nominal about 22°C) and sampled regularly. As appropriate, the concentrations of aspartame, SGMA, MCQA, and DCQA were determined by UHPLC / UV and then divided by the initial concentration to determine the recovery percentage.

[0182] Figure 1Results for three samples are shown: one sample had 3000 ppm (0.3 wt%) of aspartame, another sample had 5 wt% SGMA, and the third sample had 5 wt% SGMA and stabilizers, respectively. Aspartame has limited solubility, but 3000 ppm is comparable to the concentration of dilute syrups used to prepare some diet carbonated soft drinks with about 500 ppm aspartame. Under these conditions, the acid stability of SGMA alone is poorer than that of aspartame. After 14 days of storage, the concentration of aspartame was about 78% of the initial concentration; in other words, about 22% of the aspartame was degraded. Over the same 14 days, the concentration of SGMA in the sample containing only SGMA was about 67% of the initial concentration, degrading by about 33%. This means that SGMA degradation is 50% higher than aspartame degradation (33% vs. 22%).

[0183] In contrast, the SGMA concentration in the sample with SGMA and stabilizer was about 81% of the initial concentration at 14 days, with a degradation of 19%, which was almost 15% lower than the degradation of aspartame (19% compared to 22%). The significant effect of stabilized SGMA continued to be demonstrated over the remaining 35 days of testing, with more than 60% of the SGMA being retained by the stabilizer, while only about 38% of the SGMA was retained in the SGMA-only sample.

[0184] The terms and expressions that have been adopted are used as terms of description rather than limitation, and it is not intended that the use of such terms and expressions exclude any equivalents of the features shown and described or parts thereof, but it should be recognized that various modifications are possible within the scope of the embodiments of the present invention. Therefore, it should be understood that although the present invention has been specifically disclosed by specific embodiments and optional features, those of ordinary skill in the art may adopt modified and variant forms of the concepts disclosed herein, and these modified and variant forms are considered to be within the scope of the embodiments of the present invention.

[0185] Exemplary embodiments .

[0186] The following exemplary embodiments are provided, the numbering of which should not be construed as designating a level of importance:

[0187] Embodiment 1 provides a composition, which comprises:

[0188] one or more steviol glycoside malonates (SGMA) or salts thereof; and

[0189] A stabilizer comprising one or more caffeoyl-substituted quinic acid or a salt thereof (e.g., the stabilizer can be selected from 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, salts thereof, and combinations thereof).

[0190] Embodiment 2 provides the composition of embodiment 1, wherein the stabilizer is one or more of monocaffeoylquinic acid, dicaffeoylquinic acid, salts thereof, or combinations thereof.

[0191] Embodiment 3 provides the composition of embodiment 2, wherein the stabilizer is a mixture of:

[0192] one or more monocaffeoylquinic acids, salts thereof, or combinations thereof; and

[0193] One or more dicaffeoylquinic acids, salts thereof, or combinations thereof.

[0194] Embodiment 4 provides the composition of any one of embodiments 2 to 3, wherein the monocaffeoylquinic acid is one or more of 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, or 5-O-caffeoylquinic acid.

[0195] Embodiment 5 provides the composition of any one of embodiments 2 to 4, wherein the monocaffeoylquinate is one or more of 3-O-caffeoylquinate, 4-O-caffeoylquinate, or 5-O-caffeoylquinate.

[0196] Embodiment 6 provides the composition of any one of embodiments 2 to 5, wherein the dicaffeoylquinic acid is one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, or 4,5-dicaffeoylquinic acid.

[0197] Embodiment 7 provides the composition of any one of embodiments 2 to 6, wherein the dicaffeoylquinate is one or more of 1,3-dicaffeoylquinate, 1,4-dicaffeoylquinate, 1,5-dicaffeoylquinate, 3,4-dicaffeoylquinate, 3,5-dicaffeoylquinate, or 4,5-dicaffeoylquinate.

[0198] Embodiment 8 provides the composition of any one of embodiments 2 to 7, wherein the monocaffeoylquinate or dicaffeoylquinate comprises a counterion that is sodium, potassium, calcium, magnesium, ammonium, or a combination thereof.

[0199] Embodiment 9 provides the composition of any one of embodiments 2 to 8, wherein the monocaffeoylquinate or dicaffeoylquinate comprises a counterion that is sodium, potassium, or a combination thereof.

[0200] Embodiment 10 provides the composition of any one of embodiments 1 to 9, wherein the malonate group has the structure:

[0201]

[0202] or a salt thereof.

[0203] Embodiment 11 provides the composition of any one of embodiments 1 to 10, wherein the SGMA comprises one or more of glucose, xylose, rhamnose, or a combination thereof.

[0204] Embodiment 12 provides the composition of any one of embodiments 1 to 11, wherein the SGMA has 1 to 3 malonate groups.

[0205] Embodiment 13 provides the composition of any one of embodiments 1 to 12, wherein the SGMA has 1 malonate group.

[0206] Embodiment 14 provides the composition of any one of embodiments 1 to 13, wherein the salt of SGMA is a malonate salt comprising a counterion that is sodium, potassium, calcium, magnesium, ammonium, or a combination thereof.

[0207] Embodiment 15 provides the composition of any one of embodiments 1 to 14, wherein the salt of SGMA is a malonate salt comprising a counterion that is sodium, potassium, or a combination thereof.

[0208] Embodiment 16 provides the composition of any one of embodiments 1 to 15, wherein the SGMA has the following structure:

[0209]

[0210] or its salts;

[0211] in

[0212] At each occurrence, R 1 independently selected from -H, a malonate or a salt thereof, and a glycosidically bonded primary sugar,

[0213] at each occurrence, the primary sugar is independently selected from the group consisting of glucose, xylose, and rhamnose, and at each occurrence, the primary sugar independently optionally comprises a secondary sugar glycosidically bonded to the primary sugar, a malonate or salt thereof bonded to the primary sugar, or a combination thereof,

[0214] at each occurrence, if present, the secondary sugar is independently selected from glucose, xylose and rhamnose, and at each occurrence, the secondary sugar independently optionally comprises a tertiary sugar glycosidically bonded to the secondary sugar, a malonate or salt thereof bonded to the secondary sugar, or a combination thereof,

[0215] At each occurrence, if present, the tertiary sugar is independently selected from glucose, xylose and rhamnose, and at each occurrence, the tertiary sugar independently optionally comprises a malonate or a salt thereof bonded to the tertiary sugar, and

[0216] The SGMA comprises at least one of the primary sugars and at least one of the malonate groups or salts thereof.

[0217] Embodiment 17 provides the composition of embodiment 16, wherein the SGMA comprises at least one of the secondary sugars.

[0218] Embodiment 18 provides the composition of any one of embodiments 16 to 17, wherein the SMGA comprises at least one of the tertiary sugars.

[0219] Embodiment 19 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0220]

[0221] or its salts;

[0222] in

[0223] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0224] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0225] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0226] SGMA comprises at least one malonate ester or salt thereof.

[0227] Embodiment 20 provides the composition of embodiment 19, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0228] Embodiment 21 provides the composition of any one of embodiments 19 to 20, wherein the SGMA has the following structure:

[0229]

[0230] or a salt thereof.

[0231] Embodiment 22 provides the composition of any one of embodiments 19 to 21, wherein the SGMA has the following structure:

[0232]

[0233] or a salt thereof.

[0234] Embodiment 23 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0235]

[0236] or its salts;

[0237] in

[0238] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0239] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0240] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0241] SGMA comprises at least one malonate ester or salt thereof.

[0242] Embodiment 24 provides the composition of embodiment 23, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0243] Embodiment 25 provides the composition of any one of embodiments 23 to 24, wherein the SGMA has the following structure:

[0244]

[0245] or a salt thereof.

[0246] Embodiment 26 provides the composition of any one of embodiments 23 to 25, wherein the SGMA has the following structure:

[0247]

[0248] or a salt thereof.

[0249] Embodiment 27 provides the composition of any one of embodiments 23 to 24, wherein the SGMA has the following structure:

[0250]

[0251] or a salt thereof.

[0252] Embodiment 28 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0253]

[0254] or its salts;

[0255] in

[0256] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0257] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0258] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0259] SGMA comprises at least one malonate ester or salt thereof.

[0260] Embodiment 29 provides the composition of embodiment 28, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0261] Embodiment 30 provides the composition of any one of embodiments 28 to 29, wherein the SGMA has the following structure:

[0262]

[0263] or a salt thereof.

[0264] Embodiment 31 provides the composition of any one of embodiments 28 to 30, wherein the SGMA has the following structure:

[0265]

[0266] or a salt thereof.

[0267] Embodiment 32 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0268]

[0269] or its salts;

[0270] in

[0271] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0272] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0273] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0274] SGMA comprises at least one malonate ester or salt thereof.

[0275] Embodiment 33 provides the composition of embodiment 32, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0276] Embodiment 34 provides the composition of any one of embodiments 32 to 33, wherein the SGMA has the following structure:

[0277]

[0278] or a salt thereof.

[0279] Embodiment 35 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0280]

[0281] or its salts;

[0282] in

[0283] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0284] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0285] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0286] SGMA comprises at least one malonate ester or salt thereof.

[0287] Embodiment 36 provides the composition of embodiment 35, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0288] Embodiment 37 provides the composition of any one of embodiments 35 to 36, wherein the SGMA has the following structure:

[0289]

[0290] or a salt thereof.

[0291] Embodiment 38 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0292]

[0293] or its salts;

[0294] in

[0295] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0296] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0297] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0298] SGMA comprises at least one malonate ester or salt thereof.

[0299] Embodiment 39 provides the composition of embodiment 38, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0300] Embodiment 40 provides the composition of any one of embodiments 38 to 39, wherein the SGMA has the structure:

[0301]

[0302] or a salt thereof.

[0303] Embodiment 41 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0304]

[0305] or its salts;

[0306] in

[0307] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0308] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0309] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0310] SGMA comprises at least one malonate ester or salt thereof.

[0311] Embodiment 42 provides the composition of embodiment 41, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0312] Embodiment 43 provides the composition of any one of embodiments 41 to 42, wherein the SGMA has the following structure:

[0313]

[0314] or a salt thereof.

[0315] Embodiment 44 provides the composition of any one of embodiments 1 to 18, wherein the SGMA has the following structure:

[0316]

[0317] or its salts;

[0318] in

[0319] At each occurrence, R a independently selected from -H, a malonate or a salt thereof, and a sugar,

[0320] At each occurrence, the sugar is independently selected from glucose, xylose and rhamnose,

[0321] At each occurrence, the sugar independently optionally comprises a malonate or a salt thereof bonded to the sugar, and

[0322] SGMA comprises at least one malonate ester or salt thereof.

[0323] Embodiment 45 provides the composition of embodiment 44, wherein at each occurrence, R a Independently selected from -H and a malonate or a salt thereof.

[0324] Embodiment 46 provides the composition of any one of embodiments 44 to 45, wherein the SGMA has the structure:

[0325]

[0326] or a salt thereof.

[0327] Embodiment 47 provides the composition of any one of embodiments 44 to 46, wherein the SGMA has the structure:

[0328]

[0329] or a salt thereof.

[0330] Embodiment 48 provides the composition of any one of embodiments 1 to 47, wherein the composition is substantially free of organic acids, citric acid, malic acid, phosphates, sulfates, chromoplasts, chlorophyll, flavonoids, rutin, quercetin, quercetin, glucose, fructose, amino acids, proteins, MCQA, DCQA, or combinations thereof.

[0331] Embodiment 49 provides the composition of any one of embodiments 1 to 48, wherein the composition is substantially free of stevia plant material that is insoluble in water, ethanol, or methanol.

[0332] Embodiment 50 provides the composition of any one of embodiments 1 to 49, wherein the one or more SGMA, salts thereof, or combinations thereof are from 0.001 wt % to 99.999 wt % of the composition.

[0333] Embodiment 51 provides the composition of any one of embodiments 1 to 50, wherein the one or more SGMA, salts thereof, or combinations thereof are from 5 wt % to 99.999 wt % of the composition.

[0334] Embodiment 52 provides the composition of any one of embodiments 1 to 51, wherein the one or more SGMAs, salts thereof, or combinations thereof are from 10 wt % to 99.999 wt % of the composition.

[0335] Embodiment 53 provides the composition of any one of embodiments 1 to 52, wherein the one or more SGMA, salts thereof, or combinations thereof are from 0.01 wt % to 90 wt % of the composition.

[0336] Embodiment 54 provides the composition of any one of embodiments 1 to 53, wherein the one or more SGMAs, salts thereof, or combinations thereof are from 0.01 wt % to 30 wt % of the composition.

[0337] Embodiment 55 provides the composition of any one of embodiments 1 to 54, wherein the mass ratio of one or more SGMA, salts thereof, or combinations thereof to the stabilizer is from 0.1:1 to 10:1.

[0338] Embodiment 56 provides the composition of any one of embodiments 1 to 55, wherein the mass ratio of one or more SGMA, salts thereof, or combinations thereof to the stabilizer is 1:5 to 3:1.

[0339] Embodiment 57 provides the composition of any one of embodiments 1 to 56, wherein the composition has a concentration of one or more SGMA, salts thereof, or combinations thereof from 100 ppm to 500,000 ppm.

[0340] Embodiment 58 provides the composition of any one of embodiments 1 to 57, wherein the composition has a concentration of one or more SGMA, salts thereof, or combinations thereof from 200 ppm to 1,000 ppm.

[0341] Embodiment 59 provides the composition of any one of embodiments 1 to 58, wherein the composition has a concentration of one or more SGMA, salts thereof, or combinations thereof from 300 ppm to 700 ppm.

[0342] Embodiment 60 provides the composition of any one of embodiments 1 to 59, wherein the composition has a stabilizer concentration of 100 ppm to 500,000 ppm.

[0343] Embodiment 61 provides the composition of any one of embodiments 1 to 60, wherein the composition has a stabilizer concentration of 200 ppm to 1,000 ppm.

[0344] Embodiment 62 provides the composition of any one of embodiments 1 to 61, wherein the composition has a stabilizer concentration of 300 ppm to 700 ppm.

[0345] Embodiment 63 provides the composition of any one of embodiments 1 to 62, wherein the composition is substantially free of non-malonated steviol glycosides and salts thereof.

[0346] Embodiment 64 provides the composition of any one of embodiments 1 to 63, wherein the composition further comprises one or more non-malonated steviol glycosides, salts thereof, or combinations thereof.

[0347] Embodiment 65 provides the composition of any one of embodiments 1 to 64, wherein the composition has a ratio of non-malonated steviol glycosides, salts thereof, or combinations thereof to one or more SGMAs of 0.001:1 to 1000:1.

[0348] Embodiment 66 provides the composition of any one of embodiments 1 to 65, wherein the composition has a ratio of non-malonated steviol glycosides, salts thereof, or combinations thereof to one or more SGMAs of 0.1:1 to 1000:1.

[0349] Embodiment 67 provides the composition of any one of embodiments 1 to 66, wherein the composition has a ratio of non-malonated steviol glycosides, salts thereof, or combinations thereof to one or more SGMAs of 2:1 to 1000:1.

[0350] Embodiment 68 provides the composition of any one of embodiments 1 to 67, wherein the composition further comprises stevioside, rebaudioside A, rebaudioside C, dulcoside A, rebaudioside B, rebaudioside D, rebaudioside E, rebaudioside M, rebaudioside O, rebaudioside N, rebaudioside F, a salt thereof, or a combination thereof.

[0351] Embodiment 69 provides the composition of any one of embodiments 1 to 68, wherein the composition is an aqueous composition.

[0352] Embodiment 70 provides the composition of any one of embodiments 1 to 69, wherein at least 20% by weight of the composition is water.

[0353] Embodiment 71 provides the composition of any one of embodiments 1 to 70, wherein the composition has a pH of 1 to 9.

[0354] Embodiment 72 provides the composition of any one of embodiments 1 to 71, wherein the composition has a pH of 1.7 to 4.

[0355] Embodiment 73 provides the composition of any one of embodiments 1 to 72, wherein the composition has a pH of 2.5 to 3.5.

[0356] Embodiment 74 provides the composition of any one of embodiments 1 to 73, wherein the composition has a pH of 1.7 to 2.0.

[0357] Embodiment 75 provides the composition of any one of embodiments 1 to 74, wherein the composition has a solid form.

[0358] Embodiment 76 provides the composition of any one of embodiments 1 to 75, wherein the composition is a freeze-dried powder.

[0359] Embodiment 77 provides the composition of any one of embodiments 1 to 76, wherein the composition further comprises another stabilizer, a microbial stabilizer, another sweetener (e.g., other than SMGA or a salt thereof), a bulking agent, erythritol, a desiccant, an anti-caking agent, or a combination thereof.

[0360] Embodiment 78 provides the composition of any one of embodiments 1 to 77, wherein SGMA, a salt thereof, or a combination thereof degrades more slowly over time at pH 1.7 to 4 compared to a corresponding composition comprising less or no stabilizer.

[0361] Embodiment 79 provides the composition of any one of embodiments 1 to 78, wherein placing the composition at 22°C and pH 1.7 for 5 days results in 90% or more of the SGMA, its salt, or a combination thereof not being degraded.

[0362] Embodiment 80 provides the composition of any one of embodiments 1 to 79, wherein placing the composition at 22°C and pH 1.7 for 35 days results in 50% or more of the SGMA, a salt thereof, or a combination thereof not being degraded.

[0363] Embodiment 81 provides the composition of any one of embodiments 1 to 80, wherein the composition has improved sweetness quality compared to a corresponding composition comprising less or no stabilizer.

[0364] Embodiment 82 provides the composition of any one of embodiments 1 to 81, wherein the composition is a sweetener.

[0365] Embodiment 83 provides the composition of any one of embodiments 1 to 82, wherein the composition is a dilute syrup.

[0366] Embodiment 84 provides the composition of any one of embodiments 1 to 83, wherein the composition is a sweetened beverage.

[0367] Embodiment 85 provides the composition of any one of embodiments 1 to 84, wherein the composition is chocolate milk, tea, energy drink, drinkable yogurt, flavored water, or a combination thereof.

[0368] Embodiment 86 provides the composition of any one of embodiments 1 to 85, wherein the composition is a carbonated soft drink.

[0369] Embodiment 87 provides the composition of any one of embodiments 1 to 86, wherein the composition is a solid foodstuff.

[0370] Embodiment 88 provides the composition of any one of embodiments 1 to 87, wherein the composition is a snack, a dry fruit product, a biscuit, a cereal, a chocolate, a chewing gum, a candy, a cake, a donut, or a combination thereof.

[0371] Embodiment 89 provides the composition of any one of embodiments 1 to 88, wherein the composition is a pharmaceutical composition, a nutritional supplement, a dental composition, or a combination thereof.

[0372] Embodiment 90 provides the composition of any one of embodiments 1 to 89, wherein

[0373] 0% to 5% (by weight) of the composition is one or more of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, flavonols from agastache, rhamnitzin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; or

[0374] 0% to 3% by weight of the composition is one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or

[0375] 0% to 1% (by weight) of the composition is one or more of sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglycerides, diglycerides, triglycerides, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomaltose and inositol; or

[0376] 0% to 0.5% (by weight) of the composition is one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll; or

[0377] A combination of them.

[0378] Embodiment 91 provides the composition of any one of embodiments 1 to 90, wherein the composition comprises less than 0.3% (by weight) malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, or malic acid; or less than 0.05% (by weight) pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, or acetic acid; or less than about 0.05% (by weight) chlorophyll.

[0379] Embodiment 92 provides the composition of any one of embodiments 1 to 91, wherein the composition is free of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate and malic acid; or is free of pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate and acetic acid; or is free of chlorophyll.

[0380] Embodiment 93 provides the composition of any one of embodiments 1 to 92, wherein less than 0.1% by weight of the composition is one or more of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, acacia (arabic) gum, agar, algin-alginate, arabinoxylan, beta-glucan, beta-mannan, carrageenan, carob or locust bean gum, fenugreek gum, galactomannan, gellan gum, glucomannan or konjac gum, guar gum, hemicellulose, inulin, karaya gum, pectin, polydextrose, psyllium husk mucilage, resistant starch, tara gum, tragacanth gum, xanthan gum, cellulose, chitin, and chitosan.

[0381] Embodiment 94 provides a beverage or beverage concentrate comprising:

[0382] one or more steviol glycoside malonates (SGMA) or salts thereof; and

[0383] a stabilizer comprising one or more caffeoyl-substituted quinic acids or salts thereof (e.g., the stabilizer may be a mixture of one or more monocaffeoylquinic acids, salts thereof, or combinations thereof and one or more dicaffeoylquinic acids and salts thereof, or combinations thereof);

[0384] in

[0385] The beverage or beverage concentrate has a pH of 1.7 to 4, and / or

[0386] The mass ratio of one or more SGMA, salts thereof or combinations thereof to the stabilizer is 1:5 to 3:1.

[0387] Embodiment 95 provides a method for preparing a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof, the method comprising:

[0388] An SGMA component comprising one or more SGMA, salts thereof, or combinations thereof is combined with a stabilizer to form a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof, wherein

[0389] 0% to 5% (by weight) of the SGMA component is one or more of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, flavonols from agarwood, rhamnitzin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; or

[0390] 0% to 3% by weight of the SGMA component is one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or

[0391] 0% to 1% by weight of the SGMA component is one or more of sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglycerides, diglycerides, triglycerides, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomaltose and inositol; or

[0392] 0% to 0.5% by weight of the SGMA component is one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid, and chlorophyll; or

[0393] A combination of them.

[0394] Embodiment 96 provides the method of embodiment 95, wherein the SGMA component comprises less than 0.3% (by weight) malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, or malic acid; or less than 0.05% (by weight) pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, or acetic acid; or less than about 0.05% (by weight) chlorophyll.

[0395] Embodiment 97 provides the method of any one of embodiments 95 to 96, wherein the SGMA component is free of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, and malic acid; or is free of pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, and acetic acid; or is free of chlorophyll.

[0396] Embodiment 98 provides the method of any one of embodiments 95 to 97, wherein less than 0.1% by weight of the SGMA component is one or more of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, acacia (arabic) gum, agar, algin-alginate, arabinoxylan, beta-glucan, beta-mannan, carrageenan, carob or locust bean gum, fenugreek gum, galactomannan, gellan gum, glucomannan or konjac gum, guar gum, hemicellulose, inulin, karaya gum, pectin, polydextrose, psyllium husk mucilage, resistant starch, tara gum, tragacanth gum, xanthan gum, cellulose, chitin, and chitosan.

[0397] Embodiment 99 provides the method of any one of embodiments 95 to 98, wherein one or more steviol glycoside malonates (SGMA) or salts thereof and one or more caffeoyl-substituted quinic acids or salts thereof are provided from different sources (e.g., from different stevia leaf materials).

[0398] Embodiment 100 provides a method for preparing a composition, the method comprising:

[0399] The SGMA component is combined with a stabilizer component, wherein

[0400] The SGMA component comprises at least 30 weight percent on a dry weight basis (wt% dwb) of one or more steviol glycoside malonates (SGMA) or salts thereof, and

[0401] The stabilizer component comprises at least 30 wt. % dwb of one or more caffeoyl-substituted quinic acids or salts thereof.

[0402] Embodiment 101 provides the method of embodiment 100, wherein the composition is a beverage or a beverage concentrate, the method further comprising combining the SGMA component and the stabilizer component in an aqueous solution at a pH of 1 to 6.

[0403] Embodiment 102 provides the method of embodiment 101, wherein the SGMA component and the stabilizer component are combined prior to adding them to the aqueous solution.

[0404] Embodiment 103 provides the method of any one of embodiments 100 to 102, wherein:

[0405] 0% to 5% by weight of the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component is one or more of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, agaveflavonol, rhamnitzin, pyranoflavonols, furoflavonols, luteolin, apigenin, tangerine, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperidin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin; or

[0406] 0% to 3% by weight of the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component is one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate, and citric acid; or

[0407] 0% to 1% by weight of the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component is one or more of sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglycerides, diglycerides, triglycerides, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomaltose, and inositol; or

[0408] 0% to 0.5% by weight of the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component is one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid, and chlorophyll.

[0409] Embodiment 104 provides the method of any one of embodiments 100 to 103, wherein the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component comprises less than 0.3% by weight malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, or malic acid; or less than 0.05% by weight pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, or acetic acid; or less than about 0.05% by weight chlorophyll.

[0410] Embodiment 105 provides the method of any one of embodiments 100 to 104, wherein the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component are free of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, or malic acid; or are free of pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, and acetic acid; or are free of chlorophyll.

[0411] Embodiment 106 provides the method of any one of embodiments 100 to 105, wherein less than 0.1% by weight of the SGMA component, the stabilizer component, or both the SGMA component and the stabilizer component is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, , acacia (arabic) gum, agar, algin-alginate, arabinoxylan, beta-glucan, beta-mannan, carageenan, carob or locust bean gum, fenugreek gum, galactomannan, gellan gum, glucomannan or konjac gum, guar gum, hemicellulose, inulin, karaya gum, pectin, polydextrose, psyllium husk mucilage, resistant starch, tara gum, tragacanth gum, xanthan gum, cellulose, chitin and deacetylated chitosan.

[0412] Embodiment 107 provides a composition, beverage or beverage concentrate, or method of any one or any combination of embodiments 1 to 106, optionally configured so that all of the listed elements or options are available for selection.

Claims

1. A composition comprising: one or more steviol glycoside malonates (SGMA) or salts thereof; as well as a stabilizer comprising one or more caffeoyl-substituted quinic acid or a salt thereof; wherein the composition is a beverage or beverage concentrate having a pH of 1.7 to 4; and Wherein the SGMA or its salt has the following structure: or its salts; in At each occurrence, R 1 independently selected from -H, and glycosidically bonded primary sugars, at each occurrence, the primary sugar is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the primary sugar independently optionally comprises a secondary sugar glycosidically bonded to the primary sugar, a malonate or salt thereof bonded to the primary sugar, or a combination thereof, at each occurrence, if present, the secondary sugar is independently selected from the group consisting of glucose, xylose, and rhamnose, and at each occurrence, the secondary sugar independently optionally comprises a tertiary sugar glycosidically bonded to the secondary sugar, a malonate or salt thereof bonded to the secondary sugar, or a combination thereof, At each occurrence, if present, the tertiary saccharide is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the tertiary saccharide independently optionally comprises a malonate or a salt thereof bonded to the tertiary saccharide, and The SGMA comprises at least one of the primary sugars and at least one of a malonate group or a salt thereof on one or more of the primary, secondary, and tertiary sugars.

2. The composition according to claim 1, wherein the mass ratio of the one or more SGMAs, salts thereof or combinations thereof to the stabilizer is 0.1:1 to 10:

1.

3. A composition comprising: one or more steviol glycoside malonates (SGMA) or salts thereof; as well as a stabilizer comprising one or more caffeoyl-substituted quinic acid or a salt thereof; wherein the mass ratio of the one or more SGMA, its salt or combination thereof to the stabilizer in the composition is 1:5 to 3:1, and Wherein the SGMA or its salt has the following structure: or its salts; in At each occurrence, R 1 independently selected from -H, and glycosidically bonded primary sugars, at each occurrence, the primary sugar is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the primary sugar independently optionally comprises a secondary sugar glycosidically bonded to the primary sugar, a malonate or salt thereof bonded to the primary sugar, or a combination thereof, at each occurrence, if present, the secondary sugar is independently selected from the group consisting of glucose, xylose, and rhamnose, and at each occurrence, the secondary sugar independently optionally comprises a tertiary sugar glycosidically bonded to the secondary sugar, a malonate or salt thereof bonded to the secondary sugar, or a combination thereof, At each occurrence, if present, the tertiary saccharide is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the tertiary saccharide independently optionally comprises a malonate or a salt thereof bonded to the tertiary saccharide, and The SGMA comprises at least one of the primary sugars and at least one of a malonate group or a salt thereof on one or more of the primary, secondary, and tertiary sugars.

4. The composition of claim 3, wherein the composition is a sweetener, a diluent syrup, a sweetened beverage, a carbonated soft drink, a solid food, a pharmaceutical composition, a nutritional supplement, a dental composition, or a combination thereof.

5. The composition of any one of claims 1 to 4, wherein the one or more caffeoyl-substituted quinic acid or salt thereof is selected from the group consisting of 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, salts thereof, and combinations thereof.

6. The composition of any one of claims 1 to 4, wherein the one or more caffeoyl-substituted quinic acids or salts thereof are one or more monocaffeoylquinic acids, dicaffeoylquinic acids, salts thereof, or combinations thereof.

7. The composition according to any one of claims 1 to 4, wherein the one or more caffeoyl-substituted quinic acid or salt thereof is a mixture of: one or more monocaffeoylquinic acids, salts thereof, or combinations thereof; and One or more dicaffeoylquinic acids, salts thereof, or combinations thereof.

8. The composition of claim 6, wherein the monocaffeoylquinic acid is one or more of 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, or 5-O-caffeoylquinic acid.

9. The composition of claim 6, wherein the monocaffeoylquinate is one or more of 3-O-caffeoylquinate, 4-O-caffeoylquinate, or 5-O-caffeoylquinate.

10. The composition of claim 6, wherein the dicaffeoylquinic acid is one or more of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, or 4,5-dicaffeoylquinic acid.

11. The composition of claim 6, wherein the dicaffeoylquinate is one or more of 1,3-dicaffeoylquinate, 1,4-dicaffeoylquinate, 1,5-dicaffeoylquinate, 3,4-dicaffeoylquinate, 3,5-dicaffeoylquinate, or 4,5-dicaffeoylquinate.

12. The composition of any one of claims 1 to 4, wherein the one or more SGMAs, salts thereof, or combinations thereof are from 0.01% to 30% by weight of the composition.

13. The composition of any one of claims 1 to 4, wherein the one or more SGMAs, salts thereof, or combinations thereof are from 10% to 99.999% by weight of the composition or from 0.01% to 30% by weight of the composition.

14. The composition of any one of claims 1 to 4, wherein the composition has a stabilizer concentration of 200 ppm to 1,000 ppm.

15. The composition of any one of claims 1 to 4, wherein the SGMA, a salt thereof, or a combination thereof degrades more slowly over time at a pH of 1.7 to 4 compared to a corresponding composition comprising less or no said stabilizer.

16. The composition of any one of claims 1 to 4, wherein the composition has improved sweetness quality compared to a corresponding composition comprising less or no said stabilizer.

17. A method of preparing a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acid or salts thereof, the method comprising: combining an SGMA component comprising the one or more SGMAs, salts thereof, or combinations thereof with the stabilizer to form a composition comprising one or more steviol glycoside malonates (SGMA) or salts thereof and a stabilizer comprising one or more caffeoyl-substituted quinic acids or salts thereof, Wherein the SGMA or its salt has the following structure: or its salts; in At each occurrence, R 1 independently selected from -H, and glycosidically bonded primary sugars, at each occurrence, the primary sugar is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the primary sugar independently optionally comprises a secondary sugar glycosidically bonded to the primary sugar, a malonate or salt thereof bonded to the primary sugar, or a combination thereof, at each occurrence, if present, the secondary sugar is independently selected from the group consisting of glucose, xylose, and rhamnose, and at each occurrence, the secondary sugar independently optionally comprises a tertiary sugar glycosidically bonded to the secondary sugar, a malonate or salt thereof bonded to the secondary sugar, or a combination thereof, At each occurrence, if present, the tertiary saccharide is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the tertiary saccharide independently optionally comprises a malonate or a salt thereof bonded to the tertiary saccharide, and The SGMA comprises at least one of the primary sugars and at least one of a malonate group or a salt thereof on one or more of the primary, secondary, and tertiary sugars.

18. The method of claim 17, wherein the composition comprises less than 0.3% by weight malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, or malic acid; or less than 0.05% by weight pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, or acetic acid; or less than about 0.05% by weight chlorophyll.

19. The method of any one of claims 17 to 18, wherein the SGMA component is free of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, and malic acid; or free of pyruvate, pyruvic acid, fumarate, fumaric acid, tartrate, tartaric acid, sorbate, sorbic acid, acetate, and acetic acid; or free of chlorophyll.

20. The method of any one of claims 17 to 18, wherein less than 0.1% by weight of the SGMA component is one or more of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, acacia (arabic) gum, agar, algin-alginate, arabinoxylan, beta-glucan, beta-mannan, carrageenan, carob or locust bean gum, fenugreek gum, galactomannan, gellan gum, glucomannan or konjac gum, guar gum, hemicellulose, inulin, karaya gum, pectin, polydextrose, psyllium husk mucilage, resistant starch, tara gum, tragacanth gum, xanthan gum, cellulose, chitin, and chitosan.

21. A method for preparing a composition, the method comprising: The SGMA component is combined with a stabilizer component, wherein The SGMA component comprises at least 30 weight percent on a dry weight basis (wt% dwb) of one or more steviol glycoside malonates (SGMA) or salts thereof, and The stabilizer component comprises at least 30% dwb by weight of one or more caffeoyl-substituted quinic acids or salts thereof; Wherein the SGMA or its salt has the following structure: or its salts; in At each occurrence, R 1 independently selected from -H, and glycosidically bonded primary sugars, at each occurrence, the primary sugar is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the primary sugar independently optionally comprises a secondary sugar glycosidically bonded to the primary sugar, a malonate or salt thereof bonded to the primary sugar, or a combination thereof, at each occurrence, if present, the secondary sugar is independently selected from the group consisting of glucose, xylose, and rhamnose, and at each occurrence, the secondary sugar independently optionally comprises a tertiary sugar glycosidically bonded to the secondary sugar, a malonate or salt thereof bonded to the secondary sugar, or a combination thereof, At each occurrence, if present, the tertiary saccharide is independently selected from glucose, xylose, and rhamnose, and at each occurrence, the tertiary saccharide independently optionally comprises a malonate or a salt thereof bonded to the tertiary saccharide, and The SGMA comprises at least one of the primary sugars and at least one of a malonate group or a salt thereof on one or more of the primary, secondary, and tertiary sugars.

22. The method of claim 21, wherein the composition is a beverage or beverage concentrate, the method further comprising combining the SGMA component and the stabilizer component in an aqueous solution having a pH of 1 to 6.

23. The method of claim 22, wherein the SGMA component and the stabilizer component are combined prior to adding them to the aqueous solution.

24. The method according to any one of claims 21 to 23, wherein: 0% to 5% (by weight) of the composition is one or more of quercetin, kaempferol, myricetin, fisetin, galangin, isorhamnetin, flavonols from agarwood, rhamnetin, flavonols from pyranoflavonols, flavonols from furanos, luteolin, apigenin, tangeretin, taxifolin (or dihydroquercetin), dihydrokaempferol, hesperetin, naringenin, eriodictyol, homoeriodictyol, genistein, daidzein, glycitein, hesperidin, naringin, rutin, quercetin, luteolin-glucoside, quercetin-xyloside, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; or 0% to 3% (by weight) of the composition is one or more of malonate, malonic acid, oxalate, oxalic acid, lactate, lactic acid, succinate, succinic acid, malate, malic acid, citrate and citric acid; or 0% to 1% (by weight) of the composition is one or more of sulfate, sulfuric acid, phosphate, phosphoric acid, nitrate, nitric acid, nitrite, nitrous acid, chloride, hydrochloric acid, ammonia, ammonium, tannic acid, monoglyceride, diglyceride, triglyceride, glucose, fructose, sucrose, galactose, ribose, trehalose, trehalulose, lactose, maltose, isomaltose, isomaltulose, mannose, tagatose, arabinose, rhamnose, xylose, dextrose, erythrose, threose, maltotriose, panose, glycerol, sorbitol, mannitol, xylitol, maltitol, lactitol, erythritol, isomaltose and inositol; or 0% to 0.5% (by weight) of the composition is one or more of tartrate, tartaric acid, pyruvate, pyruvic acid, fumarate, fumaric acid, ascorbic acid, sorbate, sorbic acid, acetate, acetic acid and chlorophyll.